{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:32:47Z","timestamp":1791196367248,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Virgo Consortium"},{"name":"Dutch government","award":["FES0908"],"award-info":[{"award-number":["FES0908"]}]},{"name":"The Netherlands Genomics Initiative (NGI)","award":["050-060-452"],"award-info":[{"award-number":["050-060-452"]}]},{"DOI":"10.13039\/100007123","name":"Stanley Medical Research Institute (SMRI)","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007123","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Union FP7 SchizDX research programme","award":["223427"],"award-info":[{"award-number":["223427"]}]},{"name":"Dutch Fund for Economic Structure Reinforcement"},{"name":"NeuroBasic PharmaPhenomics","award":["0908"],"award-info":[{"award-number":["0908"]}]}],"content-domain":{"domain":["schres-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.schres.2014.02.005","type":"journal-article","created":{"date-parts":[[2014,2,27]],"date-time":"2014-02-27T04:45:45Z","timestamp":1393476345000},"page":"23-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":165,"title":["Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment"],"prefix":"10.1016","volume":"154","author":[{"given":"Lot","family":"de Witte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Tomasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Guest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Rahmoune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 S.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Bahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2014.02.005_bb0005","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1023\/A:1020720722209","article-title":"Molecular mechanisms of actions of interleukin-6 on the brain, with special reference to serotonin and the hypothalamo\u2013pituitary\u2013adrenocortical axis","volume":"24","author":"Barkhudaryan","year":"1999","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.schres.2014.02.005_bb0010","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/jn\/126.6.1515","article-title":"Modulation of inflammation and cytokine production by dietary (n-3) fatty acids","volume":"126","author":"Blok","year":"1996","journal-title":"J. Nutr."},{"key":"10.1016\/j.schres.2014.02.005_bb0015","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0006-3223(01)01324-5","article-title":"Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia","volume":"51","author":"Bocchio","year":"2002","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2014.02.005_bb0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0140-6736(03)12122-8","article-title":"The STARD initiative","volume":"361","author":"Bossuyt","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2014.02.005_bb0025","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1196\/annals.1351.006","article-title":"Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases","volume":"1069","author":"Calcagni","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.schres.2014.02.005_bb0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/B978-0-12-387718-5.00005-5","article-title":"Converging evidence of blood-based biomarkers for schizophrenia: an update","volume":"101","author":"Chan","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.schres.2014.02.005_bb0035","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3109\/08923973.2013.828744","article-title":"Regulation of macrophage immune responses by antipsychotic drugs","volume":"35","author":"Chen","year":"2013","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.schres.2014.02.005_bb0040","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1037\/0033-2909.114.3.494","article-title":"Dominance statistics: ordinal analyses to answer ordinal questions","volume":"114","author":"Cliff","year":"1993","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.schres.2014.02.005_bb0045","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1176\/appi.ajp.2007.07050740","article-title":"Infections in the CNS during childhood and the risk of subsequent psychotic illness: a cohort study of more than one million Swedish subjects","volume":"165","author":"Dalman","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2014.02.005_bb0050","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ejphar.2004.07.040","article-title":"Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity","volume":"500","author":"Dantzer","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.schres.2014.02.005_bb0055","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/oxfordjournals.schbul.a007030","article-title":"A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia","volume":"29","author":"Davies","year":"2003","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2014.02.005_bb0060","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.schres.2012.06.040","article-title":"Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein","volume":"140","author":"Dieset","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2014.02.005_bb0065","doi-asserted-by":"crossref","first-page":"e9166","DOI":"10.1371\/journal.pone.0009166","article-title":"Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case\u2013control collections","volume":"5","author":"Domenici","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.schres.2014.02.005_bb0070","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2967\/jnumed.109.066647","article-title":"Neuroinflammation in schizophrenia-related psychosis: a PET study","volume":"50","author":"Doorduin","year":"2009","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.schres.2014.02.005_bb0080","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1586\/ern.09.144","article-title":"The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder","volume":"10","author":"Drexhage","year":"2010","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.schres.2014.02.005_bb0075","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1017\/S1461145710001653","article-title":"An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces","volume":"14","author":"Drexhage","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2014.02.005_bb0085","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/B978-0-12-387718-5.00007-9","article-title":"Immune and neuroimmune alterations in mood disorders and schizophrenia","volume":"101","author":"Drexhage","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.schres.2014.02.005_bb0090","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1176\/appi.ajp.163.3.521","article-title":"Association of schizophrenia and autoimmune diseases: linkage of Danish national registers","volume":"163","author":"Eaton","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2014.02.005_bb0095","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/01621459.1987.10478410","article-title":"Better bootstrap confidence intervals","volume":"82","author":"Efron","year":"1987","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.schres.2014.02.005_bb0100","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.intimp.2012.02.010","article-title":"Contribution of brain dopamine, serotonin and opioid receptors in the mechanisms of neuroimmunomodulation: evidence from pharmacological analysis","volume":"12","author":"Idova","year":"2012","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.schres.2014.02.005_bb0105","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2174\/138955711795906941","article-title":"Anti-inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a \u2018fire extinguisher\u2019 in the brain of schizophrenia?","volume":"11","author":"Kato","year":"2011","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.schres.2014.02.005_bb0110","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2014.02.005_bb0115","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00041444-200409000-00009","article-title":"Impact of IL-1 receptor antagonist gene polymorphism on schizophrenia and bipolar disorder","volume":"14","author":"Kim","year":"2004","journal-title":"Psychiatr. Genet."},{"key":"10.1016\/j.schres.2014.02.005_bb0120","series-title":"Proceedings of the American Statistical Association Joint Statistical Meetings","article-title":"Robustness in meta-analysis: an empirical comparison of point and interval estimates of standardized mean differences and cliff's delta","author":"Kromrey","year":"2005"},{"key":"10.1016\/j.schres.2014.02.005_bb0125","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1590\/S1516-44462011005000009","article-title":"Serum levels of IL-6, IL-10 and TNF-alpha in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance","volume":"33","author":"Kunz","year":"2011","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.schres.2014.02.005_bb0130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1389203711314010005","article-title":"Neurotransmitters and microglial-mediated neuroinflammation","volume":"14","author":"Lee","year":"2013","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.schres.2014.02.005_bb0135","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0920-9964(00)00094-3","article-title":"Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor","volume":"54","author":"Maes","year":"2002","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2014.02.005_bb0140","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.psychres.2006.06.004","article-title":"T- and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment","volume":"152","author":"Maino","year":"2007","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2014.02.005_bb0145","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2014.02.005_bb0150","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2174\/157339510791823673","article-title":"Immune system and schizophrenia","volume":"6","author":"Muller","year":"2010","journal-title":"Curr. Immunol. Rev."},{"key":"10.1016\/j.schres.2014.02.005_bb0155","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.pnpbp.2012.06.024","article-title":"Relationship between inflammation and metabolic syndrome following treatment with paliperidone for schizophrenia","volume":"39","author":"Na","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2014.02.005_bb0160","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.bbi.2009.04.005","article-title":"To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers","volume":"23","author":"O'Connor","year":"2009","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.schres.2014.02.005_bb0165","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jprot.2010.01.004","article-title":"Multiple sclerosis: identification and clinical evaluation of novel CSF biomarkers","volume":"73","author":"Ottervald","year":"2010","journal-title":"J. Proteomics"},{"key":"10.1016\/j.schres.2014.02.005_bb0170","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.diabres.2004.11.007","article-title":"Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6","volume":"69","author":"Park","year":"2005","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.schres.2014.02.005_bb0175","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.schres.2012.02.019","article-title":"Schizophrenia in patients with atopic disorders with particular emphasis on asthma: a Danish population-based study","volume":"138","author":"Pedersen","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2014.02.005_bb0180","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","article-title":"Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review","volume":"63","author":"Potvin","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2014.02.005_bb0190","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4137\/BMI.S4877","article-title":"Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia","volume":"5","author":"Schwarz","year":"2010","journal-title":"Biomark. Insights"},{"key":"10.1016\/j.schres.2014.02.005_bb0185","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/mp.2011.42","article-title":"Identification of a biological signature for schizophrenia in serum","volume":"17","author":"Schwarz","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2014.02.005_bb0195","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4088\/JCP.10r06823","article-title":"Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? a meta-analysis","volume":"73","author":"Sommer","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2014.02.005_bb0200","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature08186","article-title":"Common variants conferring risk of schizophrenia","volume":"460","author":"Stefansson","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.schres.2014.02.005_bb0205","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.biopsych.2008.04.025","article-title":"Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study","volume":"64","author":"van Berckel","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2014.02.005_bb0210","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/ard.2010.148890","article-title":"Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab","volume":"71","author":"Wagner","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.schres.2014.02.005_bb0215","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.psyneuen.2010.07.017","article-title":"Interleukin-15 affects serotonin system and exerts antidepressive effects through IL15Ralpha receptor","volume":"36","author":"Wu","year":"2011","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.schres.2014.02.005_bb0220","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0022-3956(03)00072-4","article-title":"Association between IL-1beta -511C\/T and IL-1RA (86bp)n repeats polymorphisms and schizophrenia","volume":"37","author":"Zanardini","year":"2003","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2014.02.005_bb0225","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00213-008-1295-4","article-title":"Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics","volume":"201","author":"Zhang","year":"2008","journal-title":"Psychopharmacology (Berl)"}],"updated-by":[{"DOI":"10.1016\/j.schres.2014.06.006","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000}}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414000711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414000711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:51:10Z","timestamp":1565225470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996414000711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":45,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0920996414000711"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2014.02.005","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.schres.2014.06.006","asserted-by":"object"}]},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2014.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}